Denali Therapeutics DNLI has performed well in the past 12 months amid a volatile market. Shares of the company have gained ...

Following the negative Phase I trial outcome for its autoimmune disease treatment, the company is enacting lay-offs, cutting 73% of jobs.

DNL343 and fosigotifator are made to activate the ISR pathway protein eIF2B, but both failed to slow ALS progression in the HEALEY trial.

For the primary analysis, a total of 186 participants who received DNL343 treatment were compared to 139 participants who ...

According to a press release from Denali Therapeutics Inc., the small molecule DNL343 was examined in the Healey ALS Platform study, whose primary endpoint was change in disease severity measured ...

Denali Therapeutics recently disclosed the outcomes of its HEALEY trial, which evaluated DNL343, an agonist of eIF2B intended for the treatment of amyotrophic lateral sclerosis (ALS). The trial failed ...

The revision followed the announcement that Denali's DNL343, an eIF2B inhibitor, did not achieve the primary or key secondary endpoints in the phase 2/3 HEALEY trial for amyotrophic lateral sclerosis ...

DNLI's DNL343 fails to achieve the primary and secondary endpoints, as observed from an analysis of Regimen G of the phase II/III HEALEY ALS platform trial.

Denali Therapeutics Inc. DNLI announced disappointing top-line results from an analysis of Regimen G of the phase II/III HEALEY ALS Platform Trial on pipeline candidate DNL343. The HEALEY platform ...